Thus, endocrine therapy is the preferred treatment for these cancers, which commonly includes estrogen biosynthesis blockers like aromatase inhibitor agonists, selective ER modulators like tamoxifen and ER antagonists like fulvestrant [5,6]. Here, ESR1 is linked to cancer.